Pulmonary Embolism Related to Amisulpride Treatment: A Case Report
Hindawi Publishing Corporation
Case Reports in Psychiatry
Volume 2013, Article ID 718950, 3 pages
http://dx.doi.org/10.1155/2013/718950
Case Report
Pulmonary Embolism Related to Amisulpride Treatment:
A Case Report
Maria Skokou and Philippos Gourzis
Department of Psychiatry, University Hospital of Patras, School of Medicine, University of Patras, University Campus,
26504 Rio, Greece
Correspondence should be addressed to Philippos Gourzis;
Received 21 January 2013; Accepted 9 February 2013
Academic Editors: E. Jönsson, D. Matsuzawa, and F. Oyebode
Copyright © 2013 M. Skokou and P. Gourzis. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Venous thromboembolism has been associated with antipsychotic drugs, but the underlying mechanisms are largely unknown.
Hypotheses that have been made include body weight gain, sedation, enhanced platelet aggregation, increased levels of
antiphospholipid antibodies, hyperhomocysteinemia, whereas hyperprolactinemia has recently attracted attention as a potential
contributing factor. The highest risk has been demonstrated for clozapine, olanzapine, and low-potency first-generation
antipsychotics; however, presently there is no data for amisulpride. In the present paper we describe a case of pulmonary
embolism in a female bipolar patient, receiving treatment with amisulpride, aripiprazole, and paroxetine. Although a contribution
of aripiprazole and paroxetine cannot completely be ruled out, the most probable factor underlying the thromboembolic event
seems to be hyperprolactinemia, which was caused by amisulpride treatment. Increased plasma levels of prolactin should
probably be taken into account during the monitoring of antipsychotic treatment as well as in future research concerning venous
thromboembolism in psychiatric settings.
1. Introduction
Venous thromboembolism (VTE) is a common condition,
with an annual incidence of more than 1 per 1000 persons
[1]. Deep vein thrombosis (DVT) and pulmonary embolism
(PE) are two clinical expressions of VTE, the latter of which,
if untreated, is associated with a mortality rate of 30%
[2]. Risk factors can be divided in to congenital, such as
hereditary thrombophilia, and acquired, including advanced
age, obesity, surgery, malignancies, and estrogen therapy [3].
Recent research has focused on increased risk for VTE in
psychiatric settings [4].
Psychiatric conditions which have been found dangerous
in this regard are physical restraint [5], catatonia [6, 7],
and neuroleptic malignant syndrome [8]. Possible underlying mechanisms are immobilization and dehydration in
all three conditions, plus vessel injury in the situation of
physical restraint, due to heavy resistance of the patient,
or fever and rhabdomyolysis in the case of neuroleptic
malignant syndrome [4]. Higher risk for VTE has also been
demonstrated for specific classes of psychotropic drugs, most
consistently for antipsychotics [9–15]. Exact mechanisms
have not been elucidated yet, and only recently increased
prolactin has been implicated as a potential contributing
factor [16]. In the present paper we describe a case of PE most
probably related to amisulpride treatment. Amisulpride is a
Second Generation Antipsychotic (SGA) with no affinity for
serotonin receptors, but with a strong potential for increasing
prolactin [17].
2. Case Presentation
A 38-year-old woman suffering from mood disorder with
psychotic features presented to the emergency department
of our hospital complaining of left chest pain. She reported
fever during the last three days and mild dyspnea. The vital
signs recorded were blood pressure 106/64 mmHg, heart
rate 77 beats/min, respiratory rate 22 breaths/min, and body
temperature 36.8∘ C. Body Mass Index (BMI) was 26.5 kg/m2 .
There were some moist rales in the left lower lung on physical
examination, the rest of which was negative.
2
Plasma D-Dimer was 5.19 𝜇g/mL, fibrinogen was
665 𝜇g/dL, and complete blood count revealed hemoglobin
12.0 g/dL, white blood cell count 7.0 K/𝜇L, with 78%
neutrophils and platelet count 218 K/𝜇L. Liver and renal
function tests as well as cardiac enzymes were normal.
Room air blood gas analysis showed hypoxemia and
hypocapnia (pO2 76 mmHg, SaO2 95%, PCO2 38 mmHg).
Electrocardiogram showed mild sinus tachycardia, and
Computed Tomographic Pulmonary Angiography (CTPA)
revealed left lobar pulmonary artery thrombosis, regional
consolidation, and atelectasis with infection in the left
lower lung lobe, and a small pleural effusion. Based on the
history and the above results, the diagnosis of pulmonary
embolism was established. The patient was admitted
in the Department of Pathology and received heparin
intravenously at the dose of 24000 IU daily, which was
switched to acenocoumarol after three days. She was also
treated with levofloxacin 800 mg/d intravenously. As her
condition improved, she was discharged from hospital after
ten days, on acenocoumarol, which she continued taking for
six months, with International Ratio (INR) 2.5–3.0.
The patient was a housewife with three children and
had suffered her first major depressive episode, severe with
psychotic features, approximately two years before. She then
reported depressed mood, suicidal ideation, fatigue, severe
anxiety, panic attacks, insomnia, loss of body weight, irritability, ideas of reference, and persecution. She was started
on amitriptyline 20 mg/d and perfenazine 8 mg/d by her
physician, achieving only partial remission of her symptoms,
since her panic attacks remained. One year later she visited
the outpatient unit of the Psychiatry Department of our
hospital, where her treatment was gradually switched to
paroxetine, 30 mg/d, amisulpride, 400 mg/d, and alprazolam,
1 mg/d, until full remission was achieved. About five months
later, the patient complained of amenorrhea. Prolactin was
found to be high, 92 ng/mL, and amisulpride was gradually
switched to aripiprazole, 30 mg/d. By the time she was admitted to the Department of Pathology with PE, amisulpride had
already been discontinued for a period of one month, but
her prolactin was still high, 65 ng/mL. There was no history
of recent surgery or trauma, peripheral vascular disease,
cancer or cardiovascular disease, she was not receiving oral
contraceptives and her physical activity was normal. She
did not use illicit drugs or alcohol, and she smoked 10
cigarettes per day. A full work up for coagulopathy (factor V
Leiden, prothrombin deficiency, protein C and S deficiency,
antiphospholipid antibodies, activated protein C resistance,
elevated factor VIII, and hyperhomocysteinemia) did not
show any abnormalities.
The patient was followed up for another three years,
during which she demonstrated hypomanic episodes, so
the diagnosis of bipolar disorder type II was established.
Her treatment was modified to lamotrigine, 300 (...truncated)